ARNOLD FRANCES sold $185K of GENB

ARNOLD FRANCES sold 11,409 shares of Generate Biomedicines, Inc. (GENB) at $16.19 ($0.18M total) on 2026-10-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ARNOLD FRANCES
Published Nov 4, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GENB
Bearish
medium confidence
Mentioned
$GENB
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GENBBearishLow
01

Why it matters

The disclosed sale is modest in size and unlikely to move the stock significantly.

02

Market read

Minor insider sell; limited trading relevance.

03

What to watch

No other material corporate events were disclosed.

Relevance 3/10Novelty 3/10Timing: after market today

Background

SEC Form 4 filings disclose insider transactions; this is the first public report of this sale.

Company-level read

Ticker impact

$GENBBearishMedium confidence
Context

Director Arnold Frances sold 11,409 shares for $184,733 via a Form 4 filing, reducing his stake to 220,063 shares.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

A small insider sale under $200k typically has limited impact, but can prompt short‑term downside bias.

Market effects

None

None

None

Counterpoint

The sale could be routine and not indicative of future performance.

Key entities

  • Generate Biomedicines, Inc.

    Biopharma company listed on Nasdaq under ticker GENB.

  • Arnold Frances

    Director of Generate Biomedicines who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GENBHighAI 8/10

Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update

Generate Biomedicines, Inc. (GENB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update GB-0895 is being evaluated in two Phase 3 severe asthma studies for dosing twice a year A single dose of GB-0895 produced sustained pharmacological activity for at least s

Med

Zealand And Generate Biomedicines Team Up To Develop AI-Designed Therapies For Metabolic Diseases

Zealand Pharma (ZEAL) and Generate Biomedicines have partnered to develop AI-designed therapies for metabolic diseases. Zealand will handle clinical development and commercialization, while Generate will use its AI platform for drug design. Generate receives a $30M upfront payment and potential milestone payments totaling $1.2B. ZEAL stock is currently at $227.30, down 1.73%.

MedAI 9/10

Generate Biomedicines, Zealand Pharma Strike $1.2B Deal

Generate Biomedicines and Zealand Pharma agreed to a $1.2B deal to develop protein-based treatments for metabolic diseases. Generate receives $30M upfront, with additional payments tied to milestones. Generate's shares rose 5% in extended trading. The companies will collaborate on two initial programs, with an option for a third. Zealand Pharma will handle clinical development and commercialization.

$GENBMed

Zealand Pharma, Generate Biomedicines Partner To Develop AI-Designed Metabolic Disease Therapies

Zealand Pharma (ZEAL.CO) and Generate Biomedicines (GENB) partnered to develop AI-designed therapies for metabolic diseases. Generate will use its AI platform for research, while Zealand will handle clinical development and commercialization. The deal includes a $30M upfront payment and potential milestone payments totaling $1.2B. Zealand's stock closed at DKK231.30, down 1.49%.